

**PB 90 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 8) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 27 August 2024

Nikolai Tsyganov

Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 September 2024 2

National Health (Minimum Stockholding) Determination 2023 2

1 Name

(1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 8) 2024*.

(2) This instrument may also be cited as PB 90 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 September 2024 | 1 September 2024 |
| 2. Schedule 1 | 1 September 2024. | 1 September 2024 |

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 September 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral | PKU squeezie | 0 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amiodarone | Tablet containing amiodarone hydrochloride 200 mg | Oral | APO-Amiodarone | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | APO-Amitriptyline 10 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APO-Amitriptyline 25 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

4 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APO-Amitriptyline 50 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amlodipine | Tablet 10 mg (as besilate) | Oral | BTC Amlodipine | between 1 August 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Amlodipine | Tablet 5 mg (as besilate) | Oral | BTC Amlodipine | between 1 August 2024 and 31 August 2024—0 months stock by reference to usual demand |

6 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral | Atenolol‑AFT | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atenolol | Tablet 50 mg | Oral | APO-Atenolol | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Atorvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Atorvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0months stock by reference to usual demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 80 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

9 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | BOSLEER | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | BOSLEER | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

10 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Tracleer | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcitriol | Capsule 0.25 microgram | Oral | APO-Calcitriol | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Calcitriol | Capsule 0.25 microgram | Oral | Kosteo | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

11 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/12.5 | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/25 | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Capecitabine | Tablet 500 mg | Oral | Capecitabine-DRLA | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

12 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clopidogrel | Tablet 75 mg (as besilate) | Oral | BTC Clopidogrel | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

13 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diazepam | Tablet 2 mg | Oral | APO-Diazepam | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Diazepam | Tablet 5 mg | Oral | APO-Diazepam | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | APO-Diclofenac | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | APO-Diclofenac | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

14 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Entecavir Mylan | after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Entecavir Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

15 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Entecavir Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | ENTECLUDE | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTECLUDE | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

16 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | Blooms the Chemist Escitalopram | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

17 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | Blooms the Chemist Escitalopram | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

18 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fenofibrate | Tablet 145 mg | Oral | Blooms the Chemist Fenofibrate | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

19 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | BTC Fluoxetine | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

20 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glimepiride | Tablet 1 mg | Oral | Amaryl | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

21 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection | Granisetron Kabi | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

22 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ibuprofen | Tablet 400 mg | Oral | MEDICHOICE IBUPROFEN 400 mg | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

23 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan | Tablet 150 mg | Oral | Blooms the Chemist Irbesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Irbesartan | Tablet 75 mg | Oral | Avapro | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Irbesartan | Tablet 75 mg | Oral | Blooms the Chemist Irbesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

24 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | AVSARTAN HCT 150/12.5 | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Itraconazole | Capsule 100 mg | Oral | APO-Itraconazole | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

25 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Leflunomide | Tablet 10 mg | Oral | Arabloc | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | BTC Lercanidipine | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | BTC Lercanidipine | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

26 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nevirapine | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral | Viramune | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nevirapine | Tablet 200 mg | Oral | Nevirapine Viatris | after 30 November 2024— 4 months stock by reference to usual demand of both Nevirapine Viatris and Nevirapine Alphapharm added together |

27 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand  (b) after 31 December 2023—2 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nifedipine | Tablet 30 mg (controlled release) | Oral | Addos XR 30 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Nifedipine | Tablet 60 mg (controlled release) | Oral | Addos XR 60 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

28 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 10 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

29 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 2.5 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

30 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
|  |  |  |  |  |

31 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 7.5 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

32 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | BTC Perindopril | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

33 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | BTC Perindopril | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

34 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | BTC Perindopril | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

35 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pimecrolimus | Cream 10 mg per g, 15 g | Application | Elidel | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Acpio 15 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Acpio 30 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Acpio 45 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

36 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 75 mg | Oral | Blooms the Chemist Pregabalin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

37 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | Oral | Teglutik | between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Riluzole | Tablet 50 mg | Oral | APO-Riluzole | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

38 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

39 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Blooms the Chemist Venlafaxine XR | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Blooms the Chemist Venlafaxine XR | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |